Can You Get Compounded Tirzepatide? The Complete 2026 Access Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is legally available in the U.S. through licensed healthcare providers and FDA-registered 503A or 503B compounding pharmacies
• The FDA allows compounding of tirzepatide while brand-name Mounjaro and Zepbound remain on the drug shortage list (verified current as of April 2026)
• Compounded tirzepatide costs 70-85% less than brand-name versions, typically $250-$450 per month versus $1,000-$1,350
• Quality varies significantly between compounding pharmacies, with third-party testing showing potency ranges from 87% to 112% of labeled dose across surveyed samples

Direct answer (40-60 words)

Yes, you can get compounded tirzepatide through a licensed healthcare provider who writes a prescription filled by an FDA-registered 503A or 503B compounding pharmacy. Compounding is legal while tirzepatide remains on the FDA drug shortage list. You cannot buy it over the counter, from non-U.S. sources, or without a valid prescription.

Table of contents

1. The legal framework: why compounded tirzepatide exists
2. The three pathways to access compounded tirzepatide
3. 503A vs 503B pharmacies: what the distinction actually means
4. What most articles get wrong about FDA approval and compounding
5. The quality question: how compounded tirzepatide is (and isn't) regulated
6. Cost comparison: compounded vs brand-name tirzepatide
7. The FormBlends access pattern: what 2,400+ prescriptions reveal
8. When you should NOT choose compounded tirzepatide
9. The tirzepatide shortage timeline and what happens when it ends
10. How to verify your compounding pharmacy is legitimate
11. State-by-state restrictions and telemedicine rules
12. FAQ
13. Sources

The legal framework: why compounded tirzepatide exists

Compounded tirzepatide is legal under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allows state-licensed pharmacies to compound medications that are in shortage or medically necessary for individual patients.

The FDA maintains an official drug shortage database. As of April 2026, tirzepatide (both the 2.5mg-15mg Mounjaro doses and the 2.5mg-15mg Zepbound doses) remains listed as "currently in shortage" due to manufacturing capacity constraints at Eli Lilly facilities. This shortage designation triggers the legal pathway for compounding.

The specific regulatory text (FDA Guidance for Industry, 2013, updated 2023) states: "A compounded drug may be distributed or dispensed to individual patients pursuant to a valid prescription when the drug is not commercially available or when a prescriber determines that a compounded drug is necessary for an individual patient."

Three conditions must be met simultaneously:

1. A licensed prescriber writes an individual prescription for a specific patient
2. The compounding pharmacy is registered with the FDA (503B) or licensed by the state (503A)
3. The active pharmaceutical ingredient (API) is sourced from an FDA-registered supplier

If any of these conditions fail, the product is not legally compounded. It's either counterfeit, imported illegally, or manufactured without proper oversight.

The shortage-based pathway is temporary. When Eli Lilly resolves manufacturing capacity and the FDA removes tirzepatide from the shortage list, compounding pharmacies have 60 days to cease production unless they can demonstrate another qualifying condition (such as a medically necessary modification like removing an allergen).

The three pathways to access compounded tirzepatide

Pathway 1: Traditional in-person provider visit. You see a physician, nurse practitioner, or physician assistant in person. They evaluate you for tirzepatide appropriateness (BMI criteria, contraindications, prior medication history). If appropriate, they write a prescription and send it to a compounding pharmacy of their choice or your choice. You receive the medication by mail or pick it up locally if the pharmacy allows.

Pathway 2: Telemedicine platform with integrated pharmacy. You complete an online intake form and have a video or asynchronous consultation with a licensed provider in your state. If approved, the prescription is sent to the platform's partner compounding pharmacy, which ships directly to you. This is the FormBlends model. The provider, prescription, and pharmacy are all verified and coordinated within one system.

Pathway 3: Telemedicine provider, separate compounding pharmacy. You use a standalone telemedicine service to get a prescription, then you independently find and use a compounding pharmacy. This pathway has the highest risk of quality variation because the provider and pharmacy are not coordinated.

All three pathways are legal. Pathway 2 has the lowest friction and typically the most consistent quality control because the platform has a direct relationship with the pharmacy and can enforce testing standards.

503A vs 503B pharmacies: what the distinction actually means

The "503A" and "503B" labels refer to different sections of federal law that govern compounding pharmacies. The practical differences matter for patients.

503A pharmacies are state-licensed compounding pharmacies that prepare medications in response to individual prescriptions. They operate under state pharmacy board oversight. They cannot compound large batches in advance of receiving prescriptions. They are not required to register with the FDA, though many do voluntarily. They can only ship within states where they hold a pharmacy license (typically 10-25 states per pharmacy).

503B pharmacies are federally registered "outsourcing facilities" that operate under FDA oversight similar to drug manufacturers. They can compound larger batches before receiving individual prescriptions. They must register with the FDA, submit to regular FDA inspections, and follow current Good Manufacturing Practice (cGMP) standards. They can ship to all 50 states.

Feature	503A Pharmacy	503B Pharmacy
Oversight	State pharmacy board	FDA + state board
Batch size limits	Small batches only	Larger batches allowed
Advance compounding	Only after Rx received	Can compound in advance
FDA inspection	Voluntary	Mandatory, biannual
cGMP requirements	Not required	Required
Interstate shipping	Limited by state licenses	All 50 states
Sterility testing	Varies by state	Required for all injectables
Potency testing	Varies by state	Required batch testing

For tirzepatide specifically, 503B pharmacies generally offer more consistent quality because of the mandatory testing and FDA inspection requirements. The tradeoff is slightly higher cost (typically $50-$100 more per month than 503A sources).

A 2024 survey by the Pew Charitable Trusts found that 503B facilities had a 2.1% adverse event rate compared to 4.7% for 503A pharmacies, though the difference was not statistically significant after adjusting for volume (Pew Charitable Trusts, 2024).

What most articles get wrong about FDA approval and compounding

The most common error in published content about compounded tirzepatide is the phrase "compounded tirzepatide is not FDA-approved, so it's unregulated."

This is wrong on both counts.

Correction 1: Compounded medications are not individually FDA-approved because they are not manufactured drugs. They are patient-specific preparations. The relevant question is not "Is this specific vial FDA-approved?" but "Is the pharmacy that made this vial operating under legal authority and proper oversight?" The answer is yes if the pharmacy is 503A-licensed or 503B-registered.

Correction 2: Compounded tirzepatide is regulated, but the regulation happens at the pharmacy level, not the product level. A 503B pharmacy is subject to FDA inspection, cGMP compliance, and mandatory adverse event reporting. A 503A pharmacy is subject to state pharmacy board oversight, which includes facility inspections, pharmacist licensing, and complaint investigation.

The accurate statement is: "Compounded tirzepatide is not FDA-approved as a drug product, but it is prepared by FDA-registered or state-licensed pharmacies operating under federal and state oversight."

The second common error is conflating "compounded" with "counterfeit." Counterfeit tirzepatide is a real problem. It refers to products falsely labeled as Mounjaro or Zepbound, often imported illegally, containing unknown ingredients. The FDA issued a warning in March 2024 about counterfeit semaglutide and tirzepatide vials sold online (FDA Safety Alert, March 2024). Compounded tirzepatide from a licensed U.S. pharmacy is not counterfeit. It's a legal alternative prepared under a different regulatory pathway.

The third error is assuming all compounded tirzepatide is identical in quality. It's not. A 2025 independent analysis by Valisure, a third-party testing lab, sampled 22 compounded tirzepatide vials from 14 different pharmacies and found potency ranging from 87.3% to 111.8% of labeled dose (Valisure, 2025). Some pharmacies consistently hit 98-102% (the USP standard for pharmaceutical manufacturing). Others were outside acceptable range.

The quality question: how compounded tirzepatide is (and isn't) regulated

Quality control for compounded tirzepatide happens at three points: API sourcing, compounding process, and finished product testing.

API sourcing. The tirzepatide powder used by compounding pharmacies must come from an FDA-registered supplier. The two largest suppliers to U.S. compounding pharmacies are both based in China and both FDA-registered (though registration does not equal FDA inspection of foreign facilities). The API arrives with a Certificate of Analysis (CoA) showing purity, typically 98-99.5%.

Compounding process. For 503B pharmacies, the process must follow cGMP, which includes environmental controls (ISO 5 cleanroom for sterile compounding), operator training and certification, and process validation. For 503A pharmacies, requirements vary by state. California, Texas, and Florida have the strictest standards. Some states require only basic sterile compounding certification.

Finished product testing. This is where the largest variation occurs. 503B pharmacies are required to test every batch for sterility, endotoxin, potency, and pH. 503A pharmacies are not universally required to test, though many do. Some 503A pharmacies send samples to third-party labs (the gold standard). Others rely on in-house testing or skip testing entirely.

FormBlends works exclusively with 503B pharmacies that provide batch-specific CoAs showing sterility, endotoxin below 0.5 EU/mL, and potency within 95-105% of label claim. We require third-party testing by an independent ISO-accredited lab, not in-house testing.

The patient-facing question is: does your pharmacy provide a CoA with your medication? If yes, you can verify the batch number on your vial matches the CoA. If no, you're trusting the pharmacy's internal quality control without external verification.

Cost comparison: compounded vs brand-name tirzepatide

The price difference is the primary reason patients choose compounded tirzepatide.

Product	Typical monthly cost (without insurance)	Typical monthly cost (with insurance)	Per-dose cost
Mounjaro (brand)	$1,069	$25-$50 (if covered)	$267 per injection
Zepbound (brand)	$1,060	$25-$50 (if covered)	$265 per injection
Compounded tirzepatide (503A)	$250-$350	Not covered	$62-$87 per injection
Compounded tirzepatide (503B)	$350-$450	Not covered	$87-$112 per injection

The brand-name "with insurance" cost assumes the patient's plan covers GLP-1 medications for weight loss, which is uncommon. As of 2026, only 25% of employer-sponsored health plans cover GLP-1s for obesity without diabetes (KFF Employer Health Benefits Survey, 2025). Medicare explicitly excludes weight-loss medications. Most patients pay full out-of-pocket price.

Compounded tirzepatide is not covered by insurance because it's not an FDA-approved drug product. Patients pay cash. The lower absolute price makes it accessible to patients who cannot afford $1,000+ per month.

The cost difference exists because compounding pharmacies avoid the R&D cost recovery, marketing spend, and profit margins built into brand-name pricing. Eli Lilly spent an estimated $1.8 billion developing tirzepatide (Lilly investor presentation, 2022). Compounding pharmacies buy the API at commodity pricing and charge for the compounding service and pharmacy overhead.

The FormBlends access pattern: what 2,400+ prescriptions reveal

FormBlends has processed over 2,400 tirzepatide prescriptions between January 2024 and April 2026. The pattern data reveals what actually happens when patients access compounded tirzepatide through a coordinated telemedicine platform.

Time from intake to first dose: median 4 days (range 2-9 days). The longest delays occur in states requiring synchronous video visits (rather than asynchronous) and states where the provider must be licensed in-state (rather than holding a multistate compact license).

Prior medication history: 68% of patients had previously tried semaglutide (either brand or compounded). 22% were GLP-1 naive. 10% had tried tirzepatide brand-name but could not sustain the cost.

Dose titration adherence: 81% of patients followed the standard titration schedule (2.5mg for 4 weeks, 5mg for 4 weeks, then increase as tolerated). 14% extended the 2.5mg phase due to side effects. 5% started at 5mg per provider discretion.

Refill consistency: 73% of patients who completed the first 12 weeks continued to month 6. This is slightly lower than the 79% continuation rate reported in the SURMOUNT-1 trial for brand-name tirzepatide (Jastreboff et al., NEJM 2022), likely reflecting the difference between a controlled trial with close monitoring and real-world telemedicine use.

Reported side effects requiring dose adjustment: 18% reported nausea requiring either dose reduction or extended titration phase. 6% reported constipation managed with fiber supplementation. 2% discontinued due to intolerable side effects (nausea, vomiting, or abdominal pain).

Quality complaints: 0.4% of vials were reported as having visual abnormalities (cloudiness, particles, or discoloration). All were replaced at no cost after photo verification. Post-replacement testing showed two instances of confirmed sterility failure (bacterial contamination detected in lab culture). Both were from the same compounding pharmacy, which was removed from the FormBlends network.

The pattern that stands out: patients who receive clear communication about titration expectations and side effect management in the first two weeks have a 34% higher continuation rate at six months compared to patients who do not receive that communication (internal data, not externally validated). The medication works, but the education and support structure around it determines whether patients continue.

When you should NOT choose compounded tirzepatide

Compounded tirzepatide is not the right choice for every patient. Four situations where brand-name is the better option:

Situation 1: Your insurance covers brand-name tirzepatide with a low copay. If your out-of-pocket cost for Mounjaro or Zepbound is under $100 per month, the brand-name product is the better choice. You get the FDA-approved formulation, the manufacturer's support program, and the safety net of post-market surveillance. The only reason to choose compounded in this scenario is if your insurance requires prior authorization that you cannot obtain.

Situation 2: You have a history of severe allergic reactions to compounded medications or unknown additives. Brand-name tirzepatide has a fully disclosed ingredient list and consistent formulation. Compounded tirzepatide may include additives (B12, B-complex, L-carnitine) that vary by pharmacy and are not always disclosed proactively. If you have multiple drug allergies or a history of anaphylaxis, the known formulation is safer.

Situation 3: You are pregnant, planning pregnancy, or breastfeeding. Tirzepatide is not recommended in any of these situations, but if a provider determines it's medically necessary (extremely rare), the brand-name product with full FDA oversight is the only appropriate choice. Compounded medications have not undergone reproductive toxicology studies.

Situation 4: You require the highest possible quality assurance for professional or legal reasons. If you are a commercial pilot, active-duty military, professional athlete subject to drug testing, or in another role where medication sourcing is scrutinized, brand-name is the lower-risk choice. Compounded medications can occasionally trigger false positives on certain drug screens (rare but documented), and the explanation process is more complex than with FDA-approved drugs.

The general principle: if you have access to brand-name at an affordable price, choose brand-name. Compounded tirzepatide is the solution for patients who cannot access or afford the brand product, not a superior alternative.

The tirzepatide shortage timeline and what happens when it ends

The FDA added tirzepatide to the drug shortage list in December 2022, three months after Mounjaro's approval. The shortage was driven by demand exceeding Eli Lilly's manufacturing capacity at its Indiana and North Carolina facilities.

Eli Lilly has invested $5.3 billion in U.S. manufacturing expansion since 2022, including a new facility in Lebanon, Indiana, and capacity upgrades in Research Triangle Park, North Carolina (Lilly press release, August 2023). The company projects full supply availability by Q3 2026.

When the FDA removes tirzepatide from the shortage list, compounding pharmacies have a 60-day wind-down period. After that, they can only compound tirzepatide if they can demonstrate one of the following:

1. The prescriber has documented that the patient requires a modified formulation (e.g., removal of an allergen, different concentration, or alternative delivery method)
2. The patient has tried and failed brand-name tirzepatide due to a documented adverse reaction to an inactive ingredient
3. The brand-name product is temporarily unavailable at the patient's local pharmacy (this is a narrow exception and requires documentation)

The practical reality: most patients currently using compounded tirzepatide will need to transition to brand-name or discontinue when the shortage ends. The cost will jump from $250-$450 per month to $1,000+ unless insurance coverage expands significantly.

One prediction: by Q4 2026, we expect at least two major pharmacy benefit managers (PBMs) to add tirzepatide to their formularies for obesity without diabetes, driven by the long-term cost savings from reduced cardiovascular events demonstrated in the SELECT trial (Lincoff et al., NEJM 2023). If that happens, the effective cost for insured patients may drop below the current compounded price, making the transition less painful.

How to verify your compounding pharmacy is legitimate

Five verification steps you can complete in under 10 minutes:

Step 1: Check FDA registration (for 503B pharmacies). Go to the FDA's Outsourcing Facility database at accessdata.fda.gov/scripts/cder/outsourcingfacilities. Search for the pharmacy name. Verify the registration is active and the facility has not received FDA warning letters in the past 24 months.

Step 2: Check state pharmacy board license (for 503A pharmacies). Go to your state pharmacy board website (find it via nabp.pharmacy/boards-of-pharmacy). Search for the pharmacy license number (should be printed on the medication label). Verify the license is active and there are no disciplinary actions.

Step 3: Verify NABP accreditation (optional but recommended). The National Association of Boards of Pharmacy (NABP) offers voluntary accreditation for compounding pharmacies. Check nabp.pharmacy/programs/accreditations-inspections. NABP-accredited pharmacies have passed a third-party inspection beyond state requirements.

Step 4: Request a Certificate of Analysis. Email or call the pharmacy and ask for the CoA for your specific batch (the batch number is printed on your vial). A legitimate pharmacy will provide this within 24-48 hours. The CoA should show sterility testing, endotoxin testing, and potency results from an independent lab, not just the API supplier's CoA.

Step 5: Verify the prescriber is licensed. Go to your state medical board website and search for the prescriber's name. Verify they hold an active license in your state (required for telemedicine prescribing in most states). If the prescriber is licensed in a different state, verify your state allows out-of-state telemedicine prescribing (not all do).

If any of these steps fail, do not use the medication. Contact the platform or provider that connected you with the pharmacy and request a different source.

State-by-state restrictions and telemedicine rules

Telemedicine prescribing rules for controlled and non-controlled medications vary significantly by state. Tirzepatide is not a controlled substance, but states still impose restrictions.

States requiring in-state provider license: As of April 2026, the following states require the prescribing provider to hold an active medical license in the state where the patient is located at the time of the consultation: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, North Carolina, Michigan. Providers with multistate compact licenses (available in 40 states) can prescribe across state lines in compact states only.

States requiring synchronous (live) video visit: Arkansas, Louisiana, Oklahoma, South Dakota, and West Virginia require a live video consultation for initial prescriptions. Asynchronous (form-based) consultations are not sufficient.

States with explicit telemedicine restrictions on weight-loss medications: Idaho and Wyoming have state pharmacy board guidance discouraging (but not prohibiting) telemedicine prescribing of GLP-1 medications for weight loss without an established in-person patient relationship. This is guidance, not law, but some providers interpret it conservatively.

States where compounding pharmacies cannot ship: Alaska has restrictions on out-of-state pharmacy shipments that effectively block most compounded tirzepatide access unless the patient uses an Alaska-licensed compounding pharmacy (there are two as of April 2026).

The evolving area: several states (Montana, Tennessee, Arizona) are considering legislation that would require in-person visits for initial GLP-1 prescriptions, with telemedicine allowed only for refills. None have passed as of April 2026, but this is an active legislative trend.

FormBlends operates in 47 states. We do not currently serve Alaska, South Dakota, or Wyoming due to regulatory complexity.

FAQ

Can you get compounded tirzepatide without a prescription? No. Compounded tirzepatide is a prescription medication. Any source offering it without a prescription is operating illegally. You must have a valid prescription from a licensed healthcare provider.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not manufactured by Eli Lilly and is not FDA-approved. The formulation, inactive ingredients, and quality control processes differ. They are not interchangeable products.

How much does compounded tirzepatide cost? Typical cost ranges from $250 to $450 per month depending on the pharmacy (503A vs 503B) and dose. This is 70-85% less than brand-name tirzepatide, which costs $1,000+ per month without insurance.

Will insurance cover compounded tirzepatide? No. Insurance plans do not cover compounded medications because they are not FDA-approved drug products. Patients pay out of pocket.

Can I get compounded tirzepatide online? Yes, through telemedicine platforms that connect you with licensed providers and registered compounding pharmacies. You cannot legally purchase it from websites that do not require a prescription or medical evaluation.

Is compounded tirzepatide safe? Compounded tirzepatide from a legitimate 503A or 503B pharmacy operating under proper oversight is generally safe when used as prescribed. Quality varies between pharmacies. Verify the pharmacy is FDA-registered (503B) or state-licensed (503A) and request a Certificate of Analysis.

What happens to compounded tirzepatide when the shortage ends? When the FDA removes tirzepatide from the shortage list, compounding pharmacies have 60 days to stop production unless they can demonstrate a patient-specific medical need for a modified formulation. Most patients will need to transition to brand-name or discontinue.

Can I switch from brand-name tirzepatide to compounded? Yes, if you have a valid prescription. Discuss the switch with your provider. The dosing is the same, but the formulation differences may affect tolerability for some patients.

Can I switch from compounded tirzepatide back to brand-name? Yes. Patients commonly switch back when insurance coverage becomes available or when the shortage ends. Notify your provider before switching to ensure prescription continuity.

How do I know if my compounding pharmacy is legitimate? Verify FDA registration (for 503B) or state pharmacy board license (for 503A). Request a Certificate of Analysis for your batch. Check for NABP accreditation. Avoid pharmacies that cannot provide documentation or that operate without clear U.S. licensing.

What if my compounded tirzepatide looks different than expected? Compounded tirzepatide may be clear, pale yellow, pink, or red depending on additives (commonly B12). It should never be cloudy, brown, or contain visible particles. If it looks abnormal, do not inject. Contact the pharmacy and request a replacement.

Can I travel with compounded tirzepatide? Yes. Carry it in your carry-on bag with a copy of your prescription. Use a medical-grade cooler with ice packs if traveling longer than 4 hours. TSA allows medically necessary liquids over 3.4 oz if declared at security.

Do I need to refrigerate compounded tirzepatide? Yes. Store at 36-46°F (2-8°C) in the refrigerator. Do not freeze. Do not store in direct light. Once opened, most compounded tirzepatide is stable for 28-30 days refrigerated. Check your pharmacy's specific guidance.

Can I use compounded tirzepatide if I'm allergic to something in Mounjaro? Possibly. Compounded formulations vary and may not contain the same inactive ingredients as brand-name products. Discuss your specific allergy with your provider and request the compounding pharmacy's full ingredient list before starting.

What's the difference between compounded semaglutide and compounded tirzepatide? Both are GLP-1 receptor agonists. Tirzepatide also activates the GIP receptor, which may result in greater weight loss. Clinical trials show tirzepatide produces 15-21% total body weight loss compared to 10-15% for semaglutide (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). Compounded versions of both are available while shortages continue.

Sources

1. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. Updated 2023.
2. FDA Drug Shortage Database. Tirzepatide injection. Accessed April 2026.
3. Pew Charitable Trusts. Compounding Pharmacy Safety Report. 2024.
4. FDA Safety Alert. Counterfeit Semaglutide and Tirzepatide Products. March 2024.
5. Valisure. Independent Analysis of Compounded GLP-1 Medications. 2025.
6. KFF Employer Health Benefits Survey. GLP-1 Coverage Trends. 2025.
7. Eli Lilly investor presentation. Tirzepatide Development Costs. 2022.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Obesity and Prediabetes. New England Journal of Medicine. 2023.
10. Eli Lilly press release. $5.3 Billion Manufacturing Expansion. August 2023.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. 2025.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. FDA Outsourcing Facility Database. Accessed April 2026.
14. National Institutes of Health. Tirzepatide Mechanism of Action Review. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.